A new metabolic signature to predict melanoma recurrence

Keywords

cancer metabolism / melanoma / multi-omics

References

[1] Peirano D, Donoso F, Vargas S, et al. Patterns of recurrence of cutaneous melanoma: a literature review. Dermatol Pract Concept. 2023;13(4):e2023304.

[2] Davies MA, Liu P, McIntyre S, et al. Prognostic factors for survival in melanoma patients with brain metastases. Cancer. 2011;117(8):1687-1696.

[3] Skibber JM, Soong SJ, Austin L, Balch CM, Sawaya RE. Cranial irradiation after surgical excision of brain metastases in melanoma patients. Ann Surg Oncol. 1996;3(2):118-123.

[4] Szadai L, de Guedes JS, Woldmar N, et al. Mitochondrial and immune response dysregulation in melanoma recurrence. Clin Transl Med. 2023;13(11):e1495.

[5] Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol. 1927;8(6):519-530.

[6] Zong WX, Rabinowitz JD, White E. Mitochondria and Cancer. Mol Cell. 2016;61(5):667-676.

[7] Wallace DC. Mitochondria and cancer. Nat Rev Cancer. 2012;12(10):685-698.

[8] Vazquez F, Lim JH, Chim H, et al. PGC1α expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress. Cancer Cell. 2013;23(3):287-301.

[9] Tan AS, Baty JW, Dong LF, et al. Mitochondrial genome acquisition restores respiratory function and tumorigenic potential of cancer cells without mitochondrial DNA. Cell Metab. 2015;21(1):81-94.

[10] Aminzadeh-Gohari S, Weber DD, Catalano L, Feichtinger RG, Kofler B, Lang R. Targeting mitochondria in melanoma. Biomolecules. 2020;10(10):1395.

RIGHTS & PERMISSIONS

2024 2024 The Authors. Clinical and Translational Discovery published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.